MedTrace Logo

Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism

NCT04246073 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2020-07-31

No results posted yet for this study

Summary

Non interventional multi-centric study that will aim in evaluating the efficacy and safety of Fondaparinux in surgical cancer patients, identifying in parallel the most relevant and critical risk factors for Thromboembolism.

Conditions

  • Cancer
  • Cancer Diagnosis
  • Thromboembolism

Sponsors & Collaborators

  • Hellenic Society of Surgical Oncology

    lead OTHER

Principal Investigators

  • Ioannis G Karaitianos · Hellenic Society of Surgical Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-10-01
Completion
2020-12-01

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04246073 on ClinicalTrials.gov